Region Stockholm ́s Karolinska University Hospital is accredited as a Comprehensive Cancer Center for its commitment to cancer research, since 2020. Particularly, the Radiotherapy department is a Swedish leader in the clinical implementation of state-of-the-art technologies and processes in the field. A consistently high quality is achieved across a wide spectrum of treatment types, with a special focus on high-precision radiotherapy. The research areas include quantitative radiotherapy, dosimetry, and brachytherapy, for the benefit of the patients.
RS, represented by Eva Onjukka, is WP Leader for WP2 – Long-term Side Effects Modelling which focuses on developing and testing the quantitative personalised risk scores for severe cardiac and pulmonary events and second cancers. WP2 replicates available dosimetric models for late side effects in existing cohorts of breast cancer patients available to the project partners and collaborators, and integrates imaging biomarkers established by WP3 into dosimetric models.
Eva’s team includes Giovanna Gagliardi and Filippo Schiavo from the Department of Nuclear Medicine and Medical Physics, Mattias Hedman from the Department of Radiotherapy and Andri Papakonstantinou from the Department of Oncology.
For selected subcohorts, genetic and transcriptomic information will be incorporated using the signatures developed in WP4 and WP5.
RS is also part of WP1 – Coordination and Project Management, WP2 – Long-term Side Effects Modelling, WP3 – Imaging, WP4 – Genetics, WP5 – Transcriptomics, WP6 – Software Tool, WP7 – Digital Twins and WP8 – Cellular Sensitivity, WP9 – Prospective collection and WP10 – Dissemination and Exploitation.
Main building photo from website, Photographer: Carin Tellström
